Influence of ABCB1genetic polymorphisms on the antiemetic response to ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients in a tertiary care hospital

Genetic variations in the receptor, metabolizing enzymes and transporters may explain a part of the variation in anti-emetic response to ondansetron among cancer patients. This study assesses the role of ABCB1genetic polymorphisms in the anti-emetic efficacy of ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients.